| Literature DB >> 30855280 |
James V McCann1, Lin Xiao2, Dae Joong Kim3, Omar F Khan4,5, Piotr S Kowalski4, Daniel G Anderson4,5,6,7, Chad V Pecot8,9, Salma H Azam10, Joel S Parker8,9,10, Yihsuan S Tsai8, Alisa S Wolberg11, Stephen D Turner12,13, Kohei Tatsumi14, Nigel Mackman14, Andrew C Dudley3,15.
Abstract
In tumors, extravascular fibrin forms provisional scaffolds for endothelial cell (EC) growth and motility during angiogenesis. We report that fibrin-mediated angiogenesis was inhibited and tumor growth delayed following postnatal deletion of Tgfbr2 in the endothelium of Cdh5-CreERT2 Tgfbr2fl/fl mice (Tgfbr2iECKO mice). ECs from Tgfbr2iECKO mice failed to upregulate the fibrinolysis inhibitor plasminogen activator inhibitor 1 (Serpine1, also known as PAI-1), due in part to uncoupled TGF-β-mediated suppression of miR-30c. Bypassing TGF-β signaling with vascular tropic nanoparticles that deliver miR-30c antagomiRs promoted PAI-1-dependent tumor growth and increased fibrin abundance, whereas miR-30c mimics inhibited tumor growth and promoted vascular-directed fibrinolysis in vivo. Using single-cell RNA-Seq and a NanoString miRNA array, we also found that subtypes of ECs in tumors showed spectrums of Serpine1 and miR-30c expression levels, suggesting functional diversity in ECs at the level of individual cells; indeed, fresh EC isolates from lung and mammary tumor models had differential abilities to degrade fibrin and launch new vessel sprouts, a finding that was linked to their inverse expression patterns of miR-30c and Serpine1 (i.e., miR-30chi Serpine1lo ECs were poorly angiogenic and miR-30clo Serpine1hi ECs were highly angiogenic). Thus, by balancing Serpine1 expression in ECs downstream of TGF-β, miR-30c functions as a tumor suppressor in the tumor microenvironment through its ability to promote fibrin degradation and inhibit blood vessel formation.Entities:
Keywords: Breast cancer; Extracellular matrix; Oncology; Vascular Biology; endothelial cells
Mesh:
Substances:
Year: 2019 PMID: 30855280 PMCID: PMC6436861 DOI: 10.1172/JCI123106
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808